# Mosunetuzumab for CLL MRD Clearance

> **NCT07052695** · PHASE1,PHASE2 · RECRUITING · sponsor: **Inhye Ahn** · enrollment: 40 (estimated)

## Conditions studied

- Leukemia
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Lymphoma

## Interventions

- **DRUG:** Mosunetuzumab
- **DRUG:** Ibrutinib
- **DRUG:** Acalabrutinib
- **DRUG:** Zanubrutinib
- **DRUG:** Pirtobrutinib

## Key facts

- **NCT ID:** NCT07052695
- **Lead sponsor:** Inhye Ahn
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-24
- **Primary completion:** 2028-12-31
- **Final completion:** 2032-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-15

## Collaborators

- Genentech, Inc.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07052695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07052695, "Mosunetuzumab for CLL MRD Clearance". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT07052695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*